Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC 50 Debt-to-EBITDA is 6.65 as of Dec. 2025, which is 86% above its 10-year median of 3.58. GuruFocus rates LSE:SPEC with a GF Score™ of 50/100 and a GF Value™ of £0.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Inspecs Group ranks worse than 77.83% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Inspecs Group's Debt-to-EBITDA or its related term are showing as below:
LSE:SPEC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.05 Med: 3.58 Max: 10.4
Current: 4.13
During the past 10 years, the highest Debt-to-EBITDA Ratio of Inspecs Group was 10.40. The lowest was -12.05. And the median was 3.58.
LSE:SPEC's Debt-to-EBITDA is ranked worse than 77.83% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs LSE:SPEC: 4.13
Inspecs Group (LSE:SPEC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Inspecs Group Debt-to-EBITDA Related Terms
Inspecs Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Inspecs Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SPEC vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inspecs Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Inspecs Group (LSE:SPEC) has a Debt-to-EBITDA of 6.65 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Inspecs Group. This is 86% above median its historical median of 3.58. According to the industry distribution chart, Inspecs Group ranks #365 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 77.8%.
Is Inspecs Group's Debt-to-EBITDA too high?
Inspecs Group's current Debt-to-EBITDA of 6.65 is 86% above median its 10-year median of 3.58. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Inspecs Group's value of 6.65 is 315.6% above this industry median. Based on the distribution chart, Inspecs Group ranks #365 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Inspecs Group has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #365 out of 469 companies for Debt-to-EBITDA. This places Inspecs Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. Inspecs Group's value of 6.65 is 315.6% above this benchmark. While the company's 10-year median is 3.58 vs. the industry median of 1.60, Inspecs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current Debt-to-EBITDA of 6.65 is 315.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Inspecs Group. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current Debt-to-EBITDA is 6.65, which is 86% above median its own 10-year median of 3.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.58, compared to a current price of £0.97 — trading 67.2% above its estimated fair value. The current Debt-to-EBITDA is 6.65, which is 86% above median its 10-year median of 3.58 and 315.6% above the Medical Devices & Instruments industry median of 1.60. Inspecs Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current Debt-to-EBITDA is 6.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.97 is trading 67.2% above its estimated GF Value™ of £0.58.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
Debt-to-EBITDA: 6.65 (86% above median its 10-year median of 3.58)
GF Value™: £0.58 vs. price of £0.97 (67.2% above fair value)
Industry Position: 315.6% above the Medical Devices & Instruments median (#365 of 469)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
50GF Score
Get the complete analysis for LSE:SPEC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
